United Therapeutics Corporation (UTHR) - Total Assets
Based on the latest financial reports, United Therapeutics Corporation (UTHR) holds total assets worth $7.35 Billion USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See United Therapeutics Corporation (UTHR) shareholders funds for net asset value and shareholders' equity analysis.
United Therapeutics Corporation - Total Assets Trend (1998–2024)
This chart illustrates how United Therapeutics Corporation's total assets have evolved over time, based on quarterly financial data.
United Therapeutics Corporation - Asset Composition Analysis
Current Asset Composition (December 2024)
United Therapeutics Corporation's total assets of $7.35 Billion consist of 52.6% current assets and 47.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 23.1% |
| Accounts Receivable | $279.30 Million | 3.8% |
| Inventory | $157.90 Million | 2.1% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $79.60 Million | 1.1% |
| Goodwill | $32.30 Million | 0.4% |
Asset Composition Trend (1998–2024)
This chart illustrates how United Therapeutics Corporation's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see United Therapeutics Corporation stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: United Therapeutics Corporation's current assets represent 52.6% of total assets in 2024, a decrease from 89.8% in 1998.
- Cash Position: Cash and equivalents constituted 23.1% of total assets in 2024, down from 36.4% in 1998.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, an increase from 0.0% in 1998.
- Asset Diversification: The largest asset category is accounts receivable at 3.8% of total assets.
United Therapeutics Corporation Competitors by Total Assets
Key competitors of United Therapeutics Corporation based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Kangmei Pharmaceutical Co Ltd
SHG:600518
|
China | CN¥13.68 Billion |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
|
China | CN¥4.44 Billion |
|
Zhejiang Jiuzhou Pharm Co Ltd
SHG:603456
|
China | CN¥10.96 Billion |
|
Beijing Winsunny Pharmaceutical CO.LTD
SHG:601089
|
China | CN¥4.69 Billion |
|
KPC Pharmaceuticals Inc
SHG:600422
|
China | CN¥12.01 Billion |
|
Cronos Group Inc
TO:CRON
|
Canada | CA$1.18 Billion |
|
Cheng Du Sheng Nuo Biotec Co. Ltd. A
SHG:688117
|
China | CN¥1.91 Billion |
|
Jiangsu Jibeier Pharmaceutical Co Ltd
SHG:688566
|
China | CN¥2.64 Billion |
United Therapeutics Corporation - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.40 | 4.58 | 6.70 |
| Quick Ratio | 6.07 | 4.41 | 6.44 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $2.95 Billion | $3.13 Billion | $1.84 Billion |
United Therapeutics Corporation - Advanced Valuation Insights
This section examines the relationship between United Therapeutics Corporation's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.09 |
| Latest Market Cap to Assets Ratio | 2.91 |
| Asset Growth Rate (YoY) | 2.7% |
| Total Assets | $7.36 Billion |
| Market Capitalization | $21.42 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values United Therapeutics Corporation's assets at a significant premium (2.91x), suggesting investors see substantial growth potential or unique competitive advantages.
Positive Asset Growth: United Therapeutics Corporation's assets grew by 2.7% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for United Therapeutics Corporation (1998–2024)
The table below shows the annual total assets of United Therapeutics Corporation from 1998 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $7.36 Billion | +2.75% |
| 2023-12-31 | $7.17 Billion | +18.57% |
| 2022-12-31 | $6.04 Billion | +16.94% |
| 2021-12-31 | $5.17 Billion | +12.01% |
| 2020-12-31 | $4.62 Billion | +17.93% |
| 2019-12-31 | $3.91 Billion | +15.07% |
| 2018-12-31 | $3.40 Billion | +18.11% |
| 2017-12-31 | $2.88 Billion | +23.81% |
| 2016-12-31 | $2.33 Billion | +6.46% |
| 2015-12-31 | $2.18 Billion | +15.92% |
| 2014-12-31 | $1.88 Billion | -9.73% |
| 2013-12-31 | $2.09 Billion | +28.34% |
| 2012-12-31 | $1.63 Billion | +7.15% |
| 2011-12-31 | $1.52 Billion | +6.04% |
| 2010-12-31 | $1.43 Billion | +36.15% |
| 2009-12-31 | $1.05 Billion | +20.68% |
| 2008-12-31 | $871.32 Million | +48.43% |
| 2007-12-31 | $587.02 Million | +22.67% |
| 2006-12-31 | $478.55 Million | +64.22% |
| 2005-12-31 | $291.41 Million | +40.67% |
| 2004-12-31 | $207.16 Million | +15.41% |
| 2003-12-31 | $179.50 Million | -2.74% |
| 2002-12-31 | $184.57 Million | -12.99% |
| 2001-12-31 | $212.12 Million | -15.37% |
| 2000-12-31 | $250.64 Million | +318.44% |
| 1999-12-31 | $59.90 Million | +220.32% |
| 1998-12-31 | $18.70 Million | -- |
About United Therapeutics Corporation
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer;… Read more